Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study
Summary Background Phase III trials have demonstrated the efficacy and safety of ustekinumab in ulcerative colitis (UC), but few real‐life long‐term data are currently available. Aims To assess the real‐world effectiveness and safety of ustekinumab in patients with UC. Methods From January to Septem...
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2021-10, Vol.54 (7), p.944-951 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 951 |
|---|---|
| container_issue | 7 |
| container_start_page | 944 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 54 |
| creator | Fumery, Mathurin Filippi, Jérôme Abitbol, Vered Biron, Amélie Laharie, David Serrero, Melanie Altwegg, Romain Bouhnik, Yoram Peyrin‐Biroulet, Laurent Gilletta, Cyrielle Roblin, Xavier Pineton de Chambrun, Guillaume Vuitton, Lucine Bourrier, Anne Nancey, Stephane Gornet, Jean‐Marc Nahon, Stephane Bouguen, Guillaume Viennot, Stephanie Nachury, Maria Amiot, Aurelien Brazier, Franck Yzet, Clara Hebuterne, Xavier Cadiot, Guillaume Brixi, Hedia Rivière, Pauline Poullenot, Florian Treton, Xavier Stefanescu, Carmen Zallot, Camille Beaugerie, Laurent Seksik, Philippe Sokol, Harry Kirchgesner, Julien Boschetti, Gilles Flourié, Bernard Gay, Claire Danion, Pauline Venturin, Chloe Allez, Matthieu Baudry, Clotilde Pariente, Benjamin Wils, Pauline Gagnière, Charlotte Tannoury, Jenny |
| description | Summary
Background
Phase III trials have demonstrated the efficacy and safety of ustekinumab in ulcerative colitis (UC), but few real‐life long‐term data are currently available.
Aims
To assess the real‐world effectiveness and safety of ustekinumab in patients with UC.
Methods
From January to September 2019, all consecutive patients with active UC treated with ustekinumab in a GETAID centre were included. Patients were evaluated at week 52. Remission was defined as a partial Mayo Clinic score ≤2.
Results
We included 103 patients with UC (62 men; mean age: 41.2 ± 16.2 years; 52% pancolitis E3) with an insufficient response to immunosuppressants, anti‐TNFs and/or vedolizumab. At week 52, 45 (44%) patients had discontinued ustekinumab mainly due to lack of effectiveness (n = 41). The cumulative probabilities of ustekinumab persistence were 96.1%, 81.6%, 71.7% and 58.4% after 3, 6, 9 and 12 months respectively. The overall steroid‐free clinical remission rate at week 52 was 32% of whom 71% had subscores of null for rectal bleeding and stool frequency. Ten patients underwent colectomy within a median of 6.7 [4.3‐10.6] months. Adverse effects were observed in 15 (16.9%) patients; 4 (4.5%) were severe, including one patient who died from a myocardial infarction.
Conclusion
After 52 weeks, over one‐half of patients with refractory UC were still treated by ustekinumab and one‐third were in steroid‐free clinical remission.
Among 103 patients with ulcerative colitis treated with ustekinumab, one‐third achieved steroid‐free clinical remission and less than 10% were referred to surgery, after a 1‐year follow‐up period.
https://doi.org/10.1111/apt.16544 |
| doi_str_mv | 10.1111/apt.16544 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03336375v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2555105224</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3644-1476800e1cc7396b32da5f797854165692594344754910aed64390a13b5809413</originalsourceid><addsrcrecordid>eNp1kU1rGzEQhkVpaZy0h_4DQS_tYRN9r9WbSdwkYEgO7lmM5VmsdK3drrQJ219fOS4NBDqXgZln5p3hJeQTZ-e8xAX0-ZwbrdQbMuPS6Eowad6SGRPGVmLO5Qk5TemBMWZqJt6TE6mENUqbGfm9bBr0OTxixJQoxC1N0GCeaNfQMWX8GeK4hw3dQ4gZI0SPNO9wgH6iIVLOJO0hB4w50aeQd3RsfekeNlLftSGH9I0CvV6uF7dXpbLrhkxTHrfTB_KugTbhx7_5jPz4vlxf3lSru-vby8Wq8tIoVXFVmzljyL2vpTUbKbagm9rWc63K08YKbZVUqtbKcga4NUpaBlxu9JxZxeUZ-Xrcu4PW9UPYwzC5DoK7WazcocaklEbW-vHAfjmy_dD9GjFltw_JY9tCxG5MTmitOdNCqIJ-foU-dOMQyyeFqostRV6_iPuhS2nA5t8FnLmDea6Y557NK-zFkX0KLU7_B93ifn2c-AOCjpYr</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2571115805</pqid></control><display><type>article</type><title>Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study</title><source>Wiley Free Content</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Fumery, Mathurin ; Filippi, Jérôme ; Abitbol, Vered ; Biron, Amélie ; Laharie, David ; Serrero, Melanie ; Altwegg, Romain ; Bouhnik, Yoram ; Peyrin‐Biroulet, Laurent ; Gilletta, Cyrielle ; Roblin, Xavier ; Pineton de Chambrun, Guillaume ; Vuitton, Lucine ; Bourrier, Anne ; Nancey, Stephane ; Gornet, Jean‐Marc ; Nahon, Stephane ; Bouguen, Guillaume ; Viennot, Stephanie ; Nachury, Maria ; Amiot, Aurelien ; Brazier, Franck ; Yzet, Clara ; Hebuterne, Xavier ; Cadiot, Guillaume ; Brixi, Hedia ; Rivière, Pauline ; Poullenot, Florian ; Treton, Xavier ; Stefanescu, Carmen ; Zallot, Camille ; Beaugerie, Laurent ; Seksik, Philippe ; Sokol, Harry ; Kirchgesner, Julien ; Boschetti, Gilles ; Flourié, Bernard ; Gay, Claire ; Danion, Pauline ; Venturin, Chloe ; Allez, Matthieu ; Baudry, Clotilde ; Pariente, Benjamin ; Wils, Pauline ; Gagnière, Charlotte ; Tannoury, Jenny</creator><creatorcontrib>Fumery, Mathurin ; Filippi, Jérôme ; Abitbol, Vered ; Biron, Amélie ; Laharie, David ; Serrero, Melanie ; Altwegg, Romain ; Bouhnik, Yoram ; Peyrin‐Biroulet, Laurent ; Gilletta, Cyrielle ; Roblin, Xavier ; Pineton de Chambrun, Guillaume ; Vuitton, Lucine ; Bourrier, Anne ; Nancey, Stephane ; Gornet, Jean‐Marc ; Nahon, Stephane ; Bouguen, Guillaume ; Viennot, Stephanie ; Nachury, Maria ; Amiot, Aurelien ; Brazier, Franck ; Yzet, Clara ; Hebuterne, Xavier ; Cadiot, Guillaume ; Brixi, Hedia ; Rivière, Pauline ; Poullenot, Florian ; Treton, Xavier ; Stefanescu, Carmen ; Zallot, Camille ; Beaugerie, Laurent ; Seksik, Philippe ; Sokol, Harry ; Kirchgesner, Julien ; Boschetti, Gilles ; Flourié, Bernard ; Gay, Claire ; Danion, Pauline ; Venturin, Chloe ; Allez, Matthieu ; Baudry, Clotilde ; Pariente, Benjamin ; Wils, Pauline ; Gagnière, Charlotte ; Tannoury, Jenny</creatorcontrib><description>Summary
Background
Phase III trials have demonstrated the efficacy and safety of ustekinumab in ulcerative colitis (UC), but few real‐life long‐term data are currently available.
Aims
To assess the real‐world effectiveness and safety of ustekinumab in patients with UC.
Methods
From January to September 2019, all consecutive patients with active UC treated with ustekinumab in a GETAID centre were included. Patients were evaluated at week 52. Remission was defined as a partial Mayo Clinic score ≤2.
Results
We included 103 patients with UC (62 men; mean age: 41.2 ± 16.2 years; 52% pancolitis E3) with an insufficient response to immunosuppressants, anti‐TNFs and/or vedolizumab. At week 52, 45 (44%) patients had discontinued ustekinumab mainly due to lack of effectiveness (n = 41). The cumulative probabilities of ustekinumab persistence were 96.1%, 81.6%, 71.7% and 58.4% after 3, 6, 9 and 12 months respectively. The overall steroid‐free clinical remission rate at week 52 was 32% of whom 71% had subscores of null for rectal bleeding and stool frequency. Ten patients underwent colectomy within a median of 6.7 [4.3‐10.6] months. Adverse effects were observed in 15 (16.9%) patients; 4 (4.5%) were severe, including one patient who died from a myocardial infarction.
Conclusion
After 52 weeks, over one‐half of patients with refractory UC were still treated by ustekinumab and one‐third were in steroid‐free clinical remission.
Among 103 patients with ulcerative colitis treated with ustekinumab, one‐third achieved steroid‐free clinical remission and less than 10% were referred to surgery, after a 1‐year follow‐up period.
https://doi.org/10.1111/apt.16544</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>EISSN: 0269-2813</identifier><identifier>DOI: 10.1111/apt.16544</identifier><identifier>PMID: 34296456</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>Adult ; Clinical trials ; Cohort analysis ; Cohort Studies ; Colitis, Ulcerative ; Colorectal surgery ; Human health and pathology ; Humans ; Hépatology and Gastroenterology ; Immunosuppressive agents ; Inflammatory bowel disease ; Life Sciences ; Male ; Middle Aged ; Myocardial infarction ; Patients ; Pharmaceutical sciences ; Pharmacology ; Remission ; Remission (Medicine) ; Remission Induction ; Safety ; Steroids ; Treatment Outcome ; Ulcerative colitis ; Ustekinumab</subject><ispartof>Alimentary pharmacology & therapeutics, 2021-10, Vol.54 (7), p.944-951</ispartof><rights>2021 John Wiley & Sons Ltd</rights><rights>Copyright © 2021 John Wiley & Sons Ltd</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3644-1476800e1cc7396b32da5f797854165692594344754910aed64390a13b5809413</citedby><cites>FETCH-LOGICAL-c3644-1476800e1cc7396b32da5f797854165692594344754910aed64390a13b5809413</cites><orcidid>0000-0003-2536-6618 ; 0000-0001-6676-1222 ; 0000-0002-2337-2902 ; 0000-0002-4753-6676 ; 0000-0002-7929-4878 ; 0000-0001-9845-6572 ; 0000-0002-7444-5905 ; 0000-0003-2088-1442 ; 0000-0002-5787-4943 ; 0000-0002-2840-0108</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.16544$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.16544$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://hal.science/hal-03336375$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Fumery, Mathurin</creatorcontrib><creatorcontrib>Filippi, Jérôme</creatorcontrib><creatorcontrib>Abitbol, Vered</creatorcontrib><creatorcontrib>Biron, Amélie</creatorcontrib><creatorcontrib>Laharie, David</creatorcontrib><creatorcontrib>Serrero, Melanie</creatorcontrib><creatorcontrib>Altwegg, Romain</creatorcontrib><creatorcontrib>Bouhnik, Yoram</creatorcontrib><creatorcontrib>Peyrin‐Biroulet, Laurent</creatorcontrib><creatorcontrib>Gilletta, Cyrielle</creatorcontrib><creatorcontrib>Roblin, Xavier</creatorcontrib><creatorcontrib>Pineton de Chambrun, Guillaume</creatorcontrib><creatorcontrib>Vuitton, Lucine</creatorcontrib><creatorcontrib>Bourrier, Anne</creatorcontrib><creatorcontrib>Nancey, Stephane</creatorcontrib><creatorcontrib>Gornet, Jean‐Marc</creatorcontrib><creatorcontrib>Nahon, Stephane</creatorcontrib><creatorcontrib>Bouguen, Guillaume</creatorcontrib><creatorcontrib>Viennot, Stephanie</creatorcontrib><creatorcontrib>Nachury, Maria</creatorcontrib><creatorcontrib>Amiot, Aurelien</creatorcontrib><creatorcontrib>Brazier, Franck</creatorcontrib><creatorcontrib>Yzet, Clara</creatorcontrib><creatorcontrib>Hebuterne, Xavier</creatorcontrib><creatorcontrib>Cadiot, Guillaume</creatorcontrib><creatorcontrib>Brixi, Hedia</creatorcontrib><creatorcontrib>Rivière, Pauline</creatorcontrib><creatorcontrib>Poullenot, Florian</creatorcontrib><creatorcontrib>Treton, Xavier</creatorcontrib><creatorcontrib>Stefanescu, Carmen</creatorcontrib><creatorcontrib>Zallot, Camille</creatorcontrib><creatorcontrib>Beaugerie, Laurent</creatorcontrib><creatorcontrib>Seksik, Philippe</creatorcontrib><creatorcontrib>Sokol, Harry</creatorcontrib><creatorcontrib>Kirchgesner, Julien</creatorcontrib><creatorcontrib>Boschetti, Gilles</creatorcontrib><creatorcontrib>Flourié, Bernard</creatorcontrib><creatorcontrib>Gay, Claire</creatorcontrib><creatorcontrib>Danion, Pauline</creatorcontrib><creatorcontrib>Venturin, Chloe</creatorcontrib><creatorcontrib>Allez, Matthieu</creatorcontrib><creatorcontrib>Baudry, Clotilde</creatorcontrib><creatorcontrib>Pariente, Benjamin</creatorcontrib><creatorcontrib>Wils, Pauline</creatorcontrib><creatorcontrib>Gagnière, Charlotte</creatorcontrib><creatorcontrib>Tannoury, Jenny</creatorcontrib><title>Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study</title><title>Alimentary pharmacology & therapeutics</title><description>Summary
Background
Phase III trials have demonstrated the efficacy and safety of ustekinumab in ulcerative colitis (UC), but few real‐life long‐term data are currently available.
Aims
To assess the real‐world effectiveness and safety of ustekinumab in patients with UC.
Methods
From January to September 2019, all consecutive patients with active UC treated with ustekinumab in a GETAID centre were included. Patients were evaluated at week 52. Remission was defined as a partial Mayo Clinic score ≤2.
Results
We included 103 patients with UC (62 men; mean age: 41.2 ± 16.2 years; 52% pancolitis E3) with an insufficient response to immunosuppressants, anti‐TNFs and/or vedolizumab. At week 52, 45 (44%) patients had discontinued ustekinumab mainly due to lack of effectiveness (n = 41). The cumulative probabilities of ustekinumab persistence were 96.1%, 81.6%, 71.7% and 58.4% after 3, 6, 9 and 12 months respectively. The overall steroid‐free clinical remission rate at week 52 was 32% of whom 71% had subscores of null for rectal bleeding and stool frequency. Ten patients underwent colectomy within a median of 6.7 [4.3‐10.6] months. Adverse effects were observed in 15 (16.9%) patients; 4 (4.5%) were severe, including one patient who died from a myocardial infarction.
Conclusion
After 52 weeks, over one‐half of patients with refractory UC were still treated by ustekinumab and one‐third were in steroid‐free clinical remission.
Among 103 patients with ulcerative colitis treated with ustekinumab, one‐third achieved steroid‐free clinical remission and less than 10% were referred to surgery, after a 1‐year follow‐up period.
https://doi.org/10.1111/apt.16544</description><subject>Adult</subject><subject>Clinical trials</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Colitis, Ulcerative</subject><subject>Colorectal surgery</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Hépatology and Gastroenterology</subject><subject>Immunosuppressive agents</subject><subject>Inflammatory bowel disease</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial infarction</subject><subject>Patients</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacology</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Remission Induction</subject><subject>Safety</subject><subject>Steroids</subject><subject>Treatment Outcome</subject><subject>Ulcerative colitis</subject><subject>Ustekinumab</subject><issn>0269-2813</issn><issn>1365-2036</issn><issn>0269-2813</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kU1rGzEQhkVpaZy0h_4DQS_tYRN9r9WbSdwkYEgO7lmM5VmsdK3drrQJ219fOS4NBDqXgZln5p3hJeQTZ-e8xAX0-ZwbrdQbMuPS6Eowad6SGRPGVmLO5Qk5TemBMWZqJt6TE6mENUqbGfm9bBr0OTxixJQoxC1N0GCeaNfQMWX8GeK4hw3dQ4gZI0SPNO9wgH6iIVLOJO0hB4w50aeQd3RsfekeNlLftSGH9I0CvV6uF7dXpbLrhkxTHrfTB_KugTbhx7_5jPz4vlxf3lSru-vby8Wq8tIoVXFVmzljyL2vpTUbKbagm9rWc63K08YKbZVUqtbKcga4NUpaBlxu9JxZxeUZ-Xrcu4PW9UPYwzC5DoK7WazcocaklEbW-vHAfjmy_dD9GjFltw_JY9tCxG5MTmitOdNCqIJ-foU-dOMQyyeFqostRV6_iPuhS2nA5t8FnLmDea6Y557NK-zFkX0KLU7_B93ifn2c-AOCjpYr</recordid><startdate>202110</startdate><enddate>202110</enddate><creator>Fumery, Mathurin</creator><creator>Filippi, Jérôme</creator><creator>Abitbol, Vered</creator><creator>Biron, Amélie</creator><creator>Laharie, David</creator><creator>Serrero, Melanie</creator><creator>Altwegg, Romain</creator><creator>Bouhnik, Yoram</creator><creator>Peyrin‐Biroulet, Laurent</creator><creator>Gilletta, Cyrielle</creator><creator>Roblin, Xavier</creator><creator>Pineton de Chambrun, Guillaume</creator><creator>Vuitton, Lucine</creator><creator>Bourrier, Anne</creator><creator>Nancey, Stephane</creator><creator>Gornet, Jean‐Marc</creator><creator>Nahon, Stephane</creator><creator>Bouguen, Guillaume</creator><creator>Viennot, Stephanie</creator><creator>Nachury, Maria</creator><creator>Amiot, Aurelien</creator><creator>Brazier, Franck</creator><creator>Yzet, Clara</creator><creator>Hebuterne, Xavier</creator><creator>Cadiot, Guillaume</creator><creator>Brixi, Hedia</creator><creator>Rivière, Pauline</creator><creator>Poullenot, Florian</creator><creator>Treton, Xavier</creator><creator>Stefanescu, Carmen</creator><creator>Zallot, Camille</creator><creator>Beaugerie, Laurent</creator><creator>Seksik, Philippe</creator><creator>Sokol, Harry</creator><creator>Kirchgesner, Julien</creator><creator>Boschetti, Gilles</creator><creator>Flourié, Bernard</creator><creator>Gay, Claire</creator><creator>Danion, Pauline</creator><creator>Venturin, Chloe</creator><creator>Allez, Matthieu</creator><creator>Baudry, Clotilde</creator><creator>Pariente, Benjamin</creator><creator>Wils, Pauline</creator><creator>Gagnière, Charlotte</creator><creator>Tannoury, Jenny</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-2536-6618</orcidid><orcidid>https://orcid.org/0000-0001-6676-1222</orcidid><orcidid>https://orcid.org/0000-0002-2337-2902</orcidid><orcidid>https://orcid.org/0000-0002-4753-6676</orcidid><orcidid>https://orcid.org/0000-0002-7929-4878</orcidid><orcidid>https://orcid.org/0000-0001-9845-6572</orcidid><orcidid>https://orcid.org/0000-0002-7444-5905</orcidid><orcidid>https://orcid.org/0000-0003-2088-1442</orcidid><orcidid>https://orcid.org/0000-0002-5787-4943</orcidid><orcidid>https://orcid.org/0000-0002-2840-0108</orcidid></search><sort><creationdate>202110</creationdate><title>Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study</title><author>Fumery, Mathurin ; Filippi, Jérôme ; Abitbol, Vered ; Biron, Amélie ; Laharie, David ; Serrero, Melanie ; Altwegg, Romain ; Bouhnik, Yoram ; Peyrin‐Biroulet, Laurent ; Gilletta, Cyrielle ; Roblin, Xavier ; Pineton de Chambrun, Guillaume ; Vuitton, Lucine ; Bourrier, Anne ; Nancey, Stephane ; Gornet, Jean‐Marc ; Nahon, Stephane ; Bouguen, Guillaume ; Viennot, Stephanie ; Nachury, Maria ; Amiot, Aurelien ; Brazier, Franck ; Yzet, Clara ; Hebuterne, Xavier ; Cadiot, Guillaume ; Brixi, Hedia ; Rivière, Pauline ; Poullenot, Florian ; Treton, Xavier ; Stefanescu, Carmen ; Zallot, Camille ; Beaugerie, Laurent ; Seksik, Philippe ; Sokol, Harry ; Kirchgesner, Julien ; Boschetti, Gilles ; Flourié, Bernard ; Gay, Claire ; Danion, Pauline ; Venturin, Chloe ; Allez, Matthieu ; Baudry, Clotilde ; Pariente, Benjamin ; Wils, Pauline ; Gagnière, Charlotte ; Tannoury, Jenny</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3644-1476800e1cc7396b32da5f797854165692594344754910aed64390a13b5809413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Clinical trials</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Colitis, Ulcerative</topic><topic>Colorectal surgery</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Hépatology and Gastroenterology</topic><topic>Immunosuppressive agents</topic><topic>Inflammatory bowel disease</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial infarction</topic><topic>Patients</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacology</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Remission Induction</topic><topic>Safety</topic><topic>Steroids</topic><topic>Treatment Outcome</topic><topic>Ulcerative colitis</topic><topic>Ustekinumab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fumery, Mathurin</creatorcontrib><creatorcontrib>Filippi, Jérôme</creatorcontrib><creatorcontrib>Abitbol, Vered</creatorcontrib><creatorcontrib>Biron, Amélie</creatorcontrib><creatorcontrib>Laharie, David</creatorcontrib><creatorcontrib>Serrero, Melanie</creatorcontrib><creatorcontrib>Altwegg, Romain</creatorcontrib><creatorcontrib>Bouhnik, Yoram</creatorcontrib><creatorcontrib>Peyrin‐Biroulet, Laurent</creatorcontrib><creatorcontrib>Gilletta, Cyrielle</creatorcontrib><creatorcontrib>Roblin, Xavier</creatorcontrib><creatorcontrib>Pineton de Chambrun, Guillaume</creatorcontrib><creatorcontrib>Vuitton, Lucine</creatorcontrib><creatorcontrib>Bourrier, Anne</creatorcontrib><creatorcontrib>Nancey, Stephane</creatorcontrib><creatorcontrib>Gornet, Jean‐Marc</creatorcontrib><creatorcontrib>Nahon, Stephane</creatorcontrib><creatorcontrib>Bouguen, Guillaume</creatorcontrib><creatorcontrib>Viennot, Stephanie</creatorcontrib><creatorcontrib>Nachury, Maria</creatorcontrib><creatorcontrib>Amiot, Aurelien</creatorcontrib><creatorcontrib>Brazier, Franck</creatorcontrib><creatorcontrib>Yzet, Clara</creatorcontrib><creatorcontrib>Hebuterne, Xavier</creatorcontrib><creatorcontrib>Cadiot, Guillaume</creatorcontrib><creatorcontrib>Brixi, Hedia</creatorcontrib><creatorcontrib>Rivière, Pauline</creatorcontrib><creatorcontrib>Poullenot, Florian</creatorcontrib><creatorcontrib>Treton, Xavier</creatorcontrib><creatorcontrib>Stefanescu, Carmen</creatorcontrib><creatorcontrib>Zallot, Camille</creatorcontrib><creatorcontrib>Beaugerie, Laurent</creatorcontrib><creatorcontrib>Seksik, Philippe</creatorcontrib><creatorcontrib>Sokol, Harry</creatorcontrib><creatorcontrib>Kirchgesner, Julien</creatorcontrib><creatorcontrib>Boschetti, Gilles</creatorcontrib><creatorcontrib>Flourié, Bernard</creatorcontrib><creatorcontrib>Gay, Claire</creatorcontrib><creatorcontrib>Danion, Pauline</creatorcontrib><creatorcontrib>Venturin, Chloe</creatorcontrib><creatorcontrib>Allez, Matthieu</creatorcontrib><creatorcontrib>Baudry, Clotilde</creatorcontrib><creatorcontrib>Pariente, Benjamin</creatorcontrib><creatorcontrib>Wils, Pauline</creatorcontrib><creatorcontrib>Gagnière, Charlotte</creatorcontrib><creatorcontrib>Tannoury, Jenny</creatorcontrib><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fumery, Mathurin</au><au>Filippi, Jérôme</au><au>Abitbol, Vered</au><au>Biron, Amélie</au><au>Laharie, David</au><au>Serrero, Melanie</au><au>Altwegg, Romain</au><au>Bouhnik, Yoram</au><au>Peyrin‐Biroulet, Laurent</au><au>Gilletta, Cyrielle</au><au>Roblin, Xavier</au><au>Pineton de Chambrun, Guillaume</au><au>Vuitton, Lucine</au><au>Bourrier, Anne</au><au>Nancey, Stephane</au><au>Gornet, Jean‐Marc</au><au>Nahon, Stephane</au><au>Bouguen, Guillaume</au><au>Viennot, Stephanie</au><au>Nachury, Maria</au><au>Amiot, Aurelien</au><au>Brazier, Franck</au><au>Yzet, Clara</au><au>Hebuterne, Xavier</au><au>Cadiot, Guillaume</au><au>Brixi, Hedia</au><au>Rivière, Pauline</au><au>Poullenot, Florian</au><au>Treton, Xavier</au><au>Stefanescu, Carmen</au><au>Zallot, Camille</au><au>Beaugerie, Laurent</au><au>Seksik, Philippe</au><au>Sokol, Harry</au><au>Kirchgesner, Julien</au><au>Boschetti, Gilles</au><au>Flourié, Bernard</au><au>Gay, Claire</au><au>Danion, Pauline</au><au>Venturin, Chloe</au><au>Allez, Matthieu</au><au>Baudry, Clotilde</au><au>Pariente, Benjamin</au><au>Wils, Pauline</au><au>Gagnière, Charlotte</au><au>Tannoury, Jenny</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><date>2021-10</date><risdate>2021</risdate><volume>54</volume><issue>7</issue><spage>944</spage><epage>951</epage><pages>944-951</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><eissn>0269-2813</eissn><abstract>Summary
Background
Phase III trials have demonstrated the efficacy and safety of ustekinumab in ulcerative colitis (UC), but few real‐life long‐term data are currently available.
Aims
To assess the real‐world effectiveness and safety of ustekinumab in patients with UC.
Methods
From January to September 2019, all consecutive patients with active UC treated with ustekinumab in a GETAID centre were included. Patients were evaluated at week 52. Remission was defined as a partial Mayo Clinic score ≤2.
Results
We included 103 patients with UC (62 men; mean age: 41.2 ± 16.2 years; 52% pancolitis E3) with an insufficient response to immunosuppressants, anti‐TNFs and/or vedolizumab. At week 52, 45 (44%) patients had discontinued ustekinumab mainly due to lack of effectiveness (n = 41). The cumulative probabilities of ustekinumab persistence were 96.1%, 81.6%, 71.7% and 58.4% after 3, 6, 9 and 12 months respectively. The overall steroid‐free clinical remission rate at week 52 was 32% of whom 71% had subscores of null for rectal bleeding and stool frequency. Ten patients underwent colectomy within a median of 6.7 [4.3‐10.6] months. Adverse effects were observed in 15 (16.9%) patients; 4 (4.5%) were severe, including one patient who died from a myocardial infarction.
Conclusion
After 52 weeks, over one‐half of patients with refractory UC were still treated by ustekinumab and one‐third were in steroid‐free clinical remission.
Among 103 patients with ulcerative colitis treated with ustekinumab, one‐third achieved steroid‐free clinical remission and less than 10% were referred to surgery, after a 1‐year follow‐up period.
https://doi.org/10.1111/apt.16544</abstract><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34296456</pmid><doi>10.1111/apt.16544</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-2536-6618</orcidid><orcidid>https://orcid.org/0000-0001-6676-1222</orcidid><orcidid>https://orcid.org/0000-0002-2337-2902</orcidid><orcidid>https://orcid.org/0000-0002-4753-6676</orcidid><orcidid>https://orcid.org/0000-0002-7929-4878</orcidid><orcidid>https://orcid.org/0000-0001-9845-6572</orcidid><orcidid>https://orcid.org/0000-0002-7444-5905</orcidid><orcidid>https://orcid.org/0000-0003-2088-1442</orcidid><orcidid>https://orcid.org/0000-0002-5787-4943</orcidid><orcidid>https://orcid.org/0000-0002-2840-0108</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2021-10, Vol.54 (7), p.944-951 |
| issn | 0269-2813 1365-2036 0269-2813 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03336375v1 |
| source | Wiley Free Content; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Clinical trials Cohort analysis Cohort Studies Colitis, Ulcerative Colorectal surgery Human health and pathology Humans Hépatology and Gastroenterology Immunosuppressive agents Inflammatory bowel disease Life Sciences Male Middle Aged Myocardial infarction Patients Pharmaceutical sciences Pharmacology Remission Remission (Medicine) Remission Induction Safety Steroids Treatment Outcome Ulcerative colitis Ustekinumab |
| title | Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T10%3A19%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20and%20safety%20of%20ustekinumab%20maintenance%20therapy%20in%20103%20patients%20with%20ulcerative%20colitis:%20a%20GETAID%20cohort%20study&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Fumery,%20Mathurin&rft.date=2021-10&rft.volume=54&rft.issue=7&rft.spage=944&rft.epage=951&rft.pages=944-951&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.16544&rft_dat=%3Cproquest_hal_p%3E2555105224%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2571115805&rft_id=info:pmid/34296456&rfr_iscdi=true |